Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865914 | 0.89 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10150531 | 0.83 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10150528 | 0.82 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10150519 | 0.78 | RAPGEF3 (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10150526 | 0.76 | STING1 (0.56) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10239775 | 0.71 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10150532 | 0.71 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10239771 | 0.70 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10150537 | 0.69 | STING1 (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10150552 | 0.68 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | PDE4A 22/4885PDE4B 28/4885PDE4C 23/4885 |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | PDE4A 22/4885PDE4B 28/4885PDE4C 23/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | PDE4A 22/4885PDE4B 28/4885PDE4C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.